Relay Therapeutics Inc
RLAY
NASDAQ
Biotechnology
$19.86
USD
-0.07 (-0.35%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $4.37B
Volume 1.5M
Revenue
$10.35M
TTM
+23.9%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-286.04M
TTM
+8.2%
YoY
Operating Cash Flow
$-212.21M
TTM
+18.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.7 | 0.0 | 7.0 | 3.0 | 0.4 |
YoY Growth | — | — | — | -60.9% | -48.3% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.7 | 0.0 | 7.0 | 3.0 | 0.4 |
Selling, General & Administrative | 13.6 | 12.1 | 12.2 | 11.0 | 14.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
Total Operating Expenses | 77.5 | 80.4 | 67.6 | 81.6 | 91.2 |
Operating Income | -76.8 | -80.4 | -60.6 | -78.6 | -90.8 |
EBITDA | -75.8 | -79.6 | -60.0 | -78.1 | -90.5 |
Other Income / Expense | -0.6 | -0.2 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 6.5 | 6.2 | 5.7 | 5.4 | 7.1 |
Income Before Income Taxes | -70.4 | -74.1 | -54.9 | -73.3 | -83.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -70.4 | -74.1 | -54.9 | -73.3 | -83.7 |
Consolidated Net Income / Loss | -70.4 | -74.1 | -54.9 | -73.3 | -83.7 |
Net Income Attributable to Common Shareholders | -70.4 | -74.1 | -54.9 | -73.5 | -83.7 |
Basic EPS | -$0.41 | -$0.43 | -$0.32 | -$0.41 | -$0.41 |
Diluted EPS | -$0.41 | -$0.43 | -$0.32 | -$0.41 | -$0.41 |
Basic Shares Outstanding | 171.3M | 172.4M | 173.5M | 179.8M | 202.8M |
Diluted Shares Outstanding | 171.3M | 172.4M | 173.5M | 179.8M | 202.8M |